西那卡塞片联合骨化三醇胶丸治疗血液透析伴高钙血症的临床研究

发布时间：2018-05-14 18:56

本文选题：西那卡塞片 + 骨化三醇胶丸　；参考：《中国临床药理学杂志》2017年23期

【摘要】：目的观察西那卡塞片联合骨化三醇胶丸治疗血液透析伴高钙血症的临床疗效和安全性。方法将48例持续性血液透析伴高钙血症患者随机分为对照组24例和试验组24例。对照组予以西那卡塞每次25 mg,qd,口服;试验组在对照组治疗的基础上,加用骨化三醇胶丸每次0.25μg,每周3次,口服。2组患者均治疗3个月。比较2组患者的临床疗效、血清钙和磷浓度、全段甲状旁腺激素(I-PTH)水平,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为91.67%(22例/24例)和66.67%(16例/24例),差异有统计学意义(P0.05)。治疗后,试验组和对照组的钙浓度分别为(2.91±0.37)和(2.28±0.21)mmol·L~(-1),磷浓度分别为(1.35±0.17)和(1.55±0.21)mmol·L~(-1),I-PTH分别为(261.47±30.18)和(301.38±43.05)pg·m L~(-1),差异均有统计学意义(均P0.05)。试验组发生药物不良反应有肌肉疼痛、恶心呕吐和高血压,对照组发生药物不良反应有肌肉疼痛、恶心呕吐和腹泻。试验组和对照组的总药物不良反应发生率分别为12.50%和16.67%,差异无统计学意义(P0.05)。结论西那卡塞片联合骨化三醇胶丸治疗血液透析伴高钙血症的临床疗效,可显著地降低血清钙和磷浓度、以及I-PTH水平,且不增加药物不良反应的发生率。
[Abstract]:Objective to observe the clinical efficacy and safety of Xenakaset tablets combined with ossification triol colloid pill in the treatment of hemodialysis with hypercalcemia. Methods 48 patients with continuous hemodialysis and hypercalcemia were randomly divided into control group (n = 24) and trial group (n = 24). The control group was given 25 mg / d of silacarabine, and the experimental group was treated with 0.25 渭 g of oscitic triol gel pill 3 times a week for 3 months on the basis of the treatment in the control group. The clinical efficacy, serum calcium and phosphorus concentrations, total parathyroid hormone (PTH) levels and adverse drug reactions were compared between the two groups. Results after treatment, the total effective rates of the test group and the control group were 91.67 and 22 / 24, respectively. The difference was statistically significant (P 0.05). After treatment, the calcium concentrations of the experimental group and the control group were 2.91 卤0.37) and 2.28 卤0.21)mmol / L ~ (-1), P = 1.35 卤0.17) and 1.55 卤0.21)mmol ~ (-1) ~ (-1) ~ (-1) PTH, respectively, and 301.38 卤43.05)pg ~ (-1) 43.05)pg / L ~ (-1), respectively (P < 0.05). The adverse drug reactions in the trial group were muscle pain, nausea, vomiting and hypertension, while in the control group they were muscle pain, nausea and vomiting and diarrhea. The incidence of total adverse drug reactions in the test group and the control group were 12.50% and 16.67%, respectively, with no significant difference (P 0.05). Conclusion the clinical curative effect of Xinakaset tablet combined with ossifying triol colloidal pill on hemodialysis with hypercalcemia can significantly reduce serum calcium and phosphorus levels and I-PTH level and do not increase the incidence of adverse drug reactions.
【作者单位】：唐山市工人医院肾内科;
【分类号】：R692.5

【相似文献】